Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
NCT03239899Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Apr 2018
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in human immunodeficiency virus infection (HIV), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Frequency of Grade 3 or Higher Adverse Events up to 52 weeks. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03239899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239899.